Morphosys Ag logo

Morphosys Ag Share Price (NASDAQ: MOR)

-18.96

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 2 Aug 2024

Check the interactive Morphosys Ag Stock chart to analyse performance

Morphosys Ag Key Stats

Check Morphosys Ag key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$18.96
Open
$18.38
Market Capitalization
$2.9B
Today's Volume
$18.3K
Revenue TTM
$241.5M
EBITDA
$-444.9M
Earnings Per Share (EPS)
$-1.5
Profit Margin
-190.61%
Quarterly Earnings Growth YOY
-0.87%
Return On Equity TTM
-183.8%

Global Institutional Holdings in Morphosys Ag

  • Name

    Holdings %

  • Glazer Capital, LLC

    0.96%

  • Balyasny Asset Management LLC

    0.87%

  • UBS Group AG

    0.78%

  • BlackRock Inc

    0.68%

  • Carlson Capital LP

    0.63%

  • TANG CAPITAL MANAGEMENT LLC

    0.53%

Analyst Recommendation on Morphosys Ag Stock

Rating
Trend

Hold

    43%Buy

    56%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Morphosys Ag(by analysts ranked 0 to 5 stars)

About Morphosys Ag

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.
Organization
Morphosys Ag
Employees
464
CEO
Ms. Charlotte Lohmann
Industry
Health Technology

Important FAQs about investing in MOR Stock from India :

What is Morphosys Ag share price today?

Morphosys Ag share price today is as on at the close of the market. Morphosys Ag share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Morphosys Ag share?

Morphosys Ag share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Morphosys Ag stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Morphosys Ag Stock (MOR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Morphosys Ag on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Morphosys Ag Shares .

What is the minimum amount required to buy Morphosys Ag Stock (MOR) from India?

Indian investors can start investing in Morphosys Ag (MOR) shares with as little as ₹88.3 or $1 (as of September 15, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹883.00 in Morphosys Ag stock (as per the Rupee-Dollar exchange rate as on September 15, 2025). Learn more about fractional shares .

What are the returns that Morphosys Ag has given to Indian investors in the last 5 years?

Morphosys Ag stock has given 0.0% share price returns and 20.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?